This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Covetrus Past Earnings Performance

Past criteria checks 0/6

Key information

-7.8%

Earnings growth rate

-9.8%

EPS growth rate

Healthcare Industry Growth8.5%
Revenue growth rate7.1%
Return on equity-0.9%
Net Margin-0.3%
Last Earnings Update30 Jun 2022

Recent past performance updates

Recent updates

Covetrus GAAP EPS of -$0.03 misses by $0.06, revenue of $1.22B in-line

Aug 04

Clayton, Dubilier & Rice/TPG Are Not Offering Fair Value To Covetrus Shareholders

Jun 02

Covetrus, Inc.'s (NASDAQ:CVET) Intrinsic Value Is Potentially 98% Above Its Share Price

May 02
Covetrus, Inc.'s (NASDAQ:CVET) Intrinsic Value Is Potentially 98% Above Its Share Price

Are Investors Undervaluing Covetrus, Inc. (NASDAQ:CVET) By 40%?

Jan 07
Are Investors Undervaluing Covetrus, Inc. (NASDAQ:CVET) By 40%?

We Think Covetrus (NASDAQ:CVET) Has A Fair Chunk Of Debt

Oct 21
We Think Covetrus (NASDAQ:CVET) Has A Fair Chunk Of Debt

An Intrinsic Calculation For Covetrus, Inc. (NASDAQ:CVET) Suggests It's 37% Undervalued

Sep 16
An Intrinsic Calculation For Covetrus, Inc. (NASDAQ:CVET) Suggests It's 37% Undervalued

Estimating The Intrinsic Value Of Covetrus, Inc. (NASDAQ:CVET)

May 31
Estimating The Intrinsic Value Of Covetrus, Inc. (NASDAQ:CVET)

Covetrus, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Is Covetrus (NASDAQ:CVET) Using Too Much Debt?

May 05
Is Covetrus (NASDAQ:CVET) Using Too Much Debt?

Covetrus, Inc.: Well Positioned To Enjoy Market Crosscurrents

Apr 30

Who Has Been Selling Covetrus, Inc. (NASDAQ:CVET) Shares?

Feb 26
Who Has Been Selling Covetrus, Inc. (NASDAQ:CVET) Shares?

We Think Covetrus (NASDAQ:CVET) Has A Fair Chunk Of Debt

Jan 22
We Think Covetrus (NASDAQ:CVET) Has A Fair Chunk Of Debt

Covetrus reports Q4 net sales of prescription management business

Jan 13

Covetrus (NASDAQ:CVET) Shareholders Have Enjoyed An Impressive 106% Share Price Gain

Dec 18
Covetrus (NASDAQ:CVET) Shareholders Have Enjoyed An Impressive 106% Share Price Gain

Covetrus, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 12

Covetrus Q3 2020 Earnings Preview

Nov 09

Revenue & Expenses Breakdown
Beta

How Covetrus makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:CVET Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 224,649-137230
31 Mar 224,621-407280
31 Dec 214,575-547140
30 Sep 214,575-567090
30 Jun 214,539-907140
31 Mar 214,376-136850
31 Dec 204,339-266980
30 Sep 204,225-197000
30 Jun 204,117-9406300
31 Mar 204,100-9966880
31 Dec 193,976-9806610
30 Sep 193,871-9485760
30 Jun 193,776275870
31 Mar 193,772655040
29 Dec 183,7781014850
30 Sep 183,791695470
30 Jun 183,776745430
31 Mar 183,649675320
30 Dec 173,580644600
31 Dec 163,353704890
26 Dec 152,978604180

Quality Earnings: CVET is currently unprofitable.

Growing Profit Margin: CVET is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CVET is unprofitable, and losses have increased over the past 5 years at a rate of 7.8% per year.

Accelerating Growth: Unable to compare CVET's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CVET is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (1.9%).


Return on Equity

High ROE: CVET has a negative Return on Equity (-0.85%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.